Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
Date:7/12/2012

SAN DIEGO, July 12, 2012  /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it will report second quarter 2012 financial results after the NASDAQ Global Market closes on July 31. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the second quarter as well as provide a corporate update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... the clinical studies being conducted under the Company,s ... the issuance of the Company,s February 8, 2016, ... by the U.S. Food and Drug Administration (FDA) ... oral communication from the FDA followed by a ...
(Date:2/10/2016)... Demonstrates changes in brain ... selectivity   1 receptor agonist, ... clinical development as a new treatment for cognitive ... --> 1 receptor agonist, designed ... development as a new treatment for cognitive impairment ...
(Date:2/9/2016)... (NYSE: LDR ), a recognized leader in personal ... services and high quality medical consumable accessories, today reported ... December 31, 2015. --> ... , Revenue of $36.5 million compared to $37.5 million ... Measurement services revenues increased 2.8% year-over-year , Medical ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 09, 2016 , ... Traumatic Brian Injury is often in ... one of many possible sources: sports, car accidents, falls, work accidents, combat and ... Rehab Solutions for the Complexities of Concussions is designed for physical and ...
(Date:2/9/2016)... ... 09, 2016 , ... Center for Autism and Related Disorders ... spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering autism treatment in ... key to providing effective treatment for individuals with ASD. Now, over 1,800 low-income ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products announces today ... device, the StandUp Walker. Made entirely in the USA, the StandUp Walker is ... , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of a stand-assist ...
(Date:2/9/2016)... (PRWEB) , ... February 09, ... ... print and e-book publishing software, in partnership with Snowfall4pod Digital, creators of ... a comprehensive book publishing, content management, global distribution and print-on-demand network. , ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul McElwee, a ... they noticed their furnace not producing any heat. Shortly after entering the home, Paul ... exchanger was leaking dangerous levels of carbon monoxide into the home, at 2,000 parts ...
Breaking Medicine News(10 mins):